- 23 Mar 2022
- ICICIdirect Research
Indoco Remedies receives USFDA approval for LacosamideINDOCO - 352 Change: 7.85 (2.28 %)
News: Indoco Remedies has received final USFDA approval for Lacosamide tablets USP 50 mg, 100 mg, 150 mg and 200 mg, (generic for Vimpat Tablets of UCB). Lacosamide tablets are indicated for the prevention and control of seizures and has an estimated market size of ~ US$1.7 billion (MAT January 2022, IQVIA).
Views: Vimpat (Lacosamide) was accessed by over 8,00,000 people living with epilepsy and showed strong growth in all regions for UCB. It lost US exclusivity in March, 2022. Lacosamide presents a blockbuster generic opportunity in US amid loss of exclusivity. With Alembic and Glenmark Pharma already having approvals and multiple players lined up for this drug, gaining market share for Indoco will be a key monitorable. We expect the incremental contribution from approved drug from Q1FY23 providing additional leg of growth to Indoco’s US revenues.